东富龙科技集团股份有限公司独立董事 对第六届董事会第三次会议相关事项的独立意见 根据《中华人民共和国公司法》《上市公司独立董事规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规、 规范性文件及《公司章程》等相关规定的要求，我们作为东富龙科技集团股份有 限公司（以下简称"公司"）的第六届董事会的独立董事，我们对公司第六届董 事会第三次会议相关事项进行了认真审议，并基于独立判断立场，发表独立意见： 一、关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告的独 立意见 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等有关规定，我们对公司 2023 年半年度募集资金存放与使用的情况进行了认真核查，发表如下独立意见： 经审阅公司编制的《2023 年半年度募集资金存放与实际使用情况的专项报 告》，我们一致认为公司编制的《2023 年半年度募集资金存放与实际使用情况的 专项报告》内容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗漏， 符合《深圳证券交易所上市公司自律监管指引第 2 号——创 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-040 东富龙科技集团股份有限公司 关于证券事务代表辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）董事会于近日收到公司 证券事务代表金立先生提交的书面辞职报告。金立先生因个人原因申请辞去公司 证券事务代表职务，辞职报告自送达公司董事会之日起生效。金立先生辞职后将 不再担任公司的任何职务，由董事会秘书暂代证券事务代表职务，其辞职不会影 响公司相关工作的正常开展。 截至本公告日，金立先生未持有公司股份，亦不存在应当履行而未履行的承 诺事项。金立先生在担任公司证券事务代表期间恪尽职守、勤勉尽责，协助公司 董事会秘书履行职责，为公司的信息披露及合规运作发挥积极作用。公司及公司 董事会对其任职期间的勤勉工作以及为公司所做出的贡献表示衷心的感谢。 特此公告 东富龙科技集团股份有限公司 董事会 2023年8月29日 ...

东富龙科技集团股份有限公司 2023年半年度 募集资金存放与使用情况的专项报告 东富龙科技集团股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》（证监会公告〔2022〕15 号）、《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳证券交 易所创业板上市公司自律监管指南第 2 号——公告格式》等相关规定，东富龙科 技集团股份有限公司（以下简称"公司"、"本公司"）就 2023 年半年度募集资金存 放与实际使用情况作如下专项报告： 第一部分 2011 年公开发行募集资金 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准上海东富龙科技股份有限公司首次公 开发行股票并在创业板上市的批复》（证监许可[2010]1837 号）核准，并经深圳 证券交易所同意，本公司由主承销商招商证券有限公司（以下简称"招商证券"） 于 2011 年 1 月 24 日向社会公众首次公开发行人民币普通股（A 股）2,000 万股 （面值人民币 1 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-036 东富龙科技集团股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届董事会第三次会 议于 2023 年 8 月 17 日以电话、书面方式通知各位董事，会议于 2023 年 8 月 28 日（星期一）在公司（上海市闵行区都会路 1509 号）305 会议室以现场及通讯 相结合的方式召开。本次董事会会议应出席董事 9 名，实际出席会议董事 9 名。 会议由董事长郑效东主持。公司监事及高级管理人员列席本次会议。会议符合《公 司法》及《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《2023 年半年度报告及摘要》 董事会认为，公司《2023 年半年度报告》全文及《2023 年半年度报告摘要》 符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 内容真实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 《2023 年半年度募集资金存放与实际使用情况的专项报告》《独 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-037 募集资金的存放和管理均符合相关规定，不存在违规使用募集资金的行为，不存 在改变或变相改变募集资金投向和损害股东利益的情况。 东富龙科技集团股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届监事会第三次会 议于 2023 年 8 月 17 日以电话、书面方式通知各位监事，会议于 2023 年 8 月 28 日（星期一）在公司（上海市闵行区都会路 1509 号）305 会议室以现场方式召 开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。本次会议由 监事会主席杨东生先生主持。公司董事会秘书列席本次会议。会议符合《公司法》 及《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 监事会认为：董事会编制和审核公司《2023 年半年度报告》全文及摘要的 程序符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规 定，报告内容 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-039 东富龙科技集团股份有限公司 关于全资子公司调整产业投资基金认缴出资额的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次减少基金认缴出资额的事项不构成关联交易，也不构成《上市公司 重大资产重组管理办法》规定的重大资产重组。 2、本次减少基金认缴出资额不会影响基金的正常运作，目前基金总规模可 满足日常投资计划，符合公司战略发展需要，有利于提高资金的使用效率，不会 影响公司的持续经营能力，不存在损害公司和全体股东利益的情形。 3、调整实施过程中将受到行业政策调整、经济市场环境变化、投资标的经 营管理等因素影响，可能存在投资失败或亏损等不能实现预期收益的风险。为控 制上述风险，公司将积极与共同投资方进行协作，加强投后项目的管理，按照合 伙协议严格履行，减少不确定性。 东富龙科技集团股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召 开第六届董事会第三次会议、第六届监事会第三次会议，审议通过《关于全资子 公司调整产业投资基金认缴出资额的议案》，将公司全资子公 ...

证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2023-002 您好，感谢您的关注。目前公司协调一切资源来推进在手订 单的制造和交付，谢谢。 6、公司 2022 年核销了 2200 万应收账款，有大量知名上市 公司（康泰、金赛、辅仁、通化东宝）也在其中，请问这些费用 具体是什么？公司有严格的内控制度为何有大量对方明明有支 付力但是却回收的费用？ 您好，2200 万应收账款为按照单项计提的期末余额，不是 核销，详细情况请参见公司年报。公司对公司的资产质量一直很 关注，在会计准则的框架要求下，采用了行业里较高的测试标准， 来保证资产质量的真实性和可变现性。谢谢。 7、董事长好，我想问问根据 2022 年公司关于医疗装备及耗 材这一块的收入是 3.597 亿元，相比较 2021 年公司关于医疗装 备与耗材这一块的收入是 4.995 亿元，请问一下为什么这一块公 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与 ...

Financial Performance - The company achieved a total operating revenue of 5.469 billion yuan, representing a year-on-year growth of 30.46%[28] - The net profit attributable to shareholders was 847 million yuan, an increase of 2.27% compared to the previous year[28] - The company's total operating revenue for the year was approximately ¥5.47 billion, with a year-on-year increase of 30.50%[32] - The total operating revenue for 2022 reached ¥5,469,426,362.12, representing a year-on-year increase of 30.46% compared to ¥4,192,421,107.34 in 2021[60] - The net profit for 2022 reached CNY 903,039,034.78, up from CNY 886,168,898.32 in the previous year, representing a growth of 1.0%[126] - The basic earnings per share for 2022 was CNY 1.34, compared to CNY 1.32 in 2021, indicating a slight increase of 1.5%[126] - The total profit for 2022 was CNY 1,002,413,371.46, a decrease of 1.0% from CNY 1,019,562,424.48 in 2021[126] - The company's financial expenses for 2022 showed a significant improvement, with a net financial income of CNY -36,652,671.22 compared to CNY -4,364,888.27 in 2021[131] Revenue Breakdown - International revenue accounted for approximately 19.18% of total revenue, which was below expectations and impacted overall gross margin levels[28] - The revenue from injection machines and systems reached approximately ¥2.27 billion, with a gross profit margin of 43.22%[32] - The revenue from the Asia region was approximately ¥650.56 million, reflecting a year-on-year increase of 118.31%[32] - The company experienced a significant increase in revenue from the African market, with a year-on-year growth of 1,101.55%[32] - The revenue from South America increased by 129.32%, reaching ¥1,944,916.17, compared to ¥848,117.29 in 2021[61] - The biopharmaceutical engineering machines and systems generated ¥1,123,071,799.76, which is 20.53% of total revenue, reflecting a year-on-year increase of 23.85%[60] - The revenue from injection machines and systems was ¥2,268,041,740.72, accounting for 41.47% of total revenue, with a significant growth of 64.19% from ¥1,381,367,353.04 in 2021[60] Research and Development - The company is focusing on innovation and upgrading in the pharmaceutical equipment industry, transitioning from imitation to independent research and development[21] - The company is enhancing its research and development capabilities and expanding its product offerings to meet diverse customer needs in the pharmaceutical sector[28] - The company has made significant advancements in R&D and technology transfer, holding core technologies in the pharmaceutical equipment industry[54] - The company's R&D investment for the past three years has been consistently zero, indicating no capitalized R&D expenses[73] - R&D expenses increased by 332,848,006.52, up 16.99%, driven by enhanced R&D investment, multiple project implementations, and an increase in high-tech talent[94] - The company completed several R&D projects, including a high-temperature sterilization machine with a heat recovery rate of over 90%[1] - The company achieved a net profit increase driven by the successful development of domestic production materials for biopharmaceuticals, including disposable bioreactor bags and stirring bags, which align with market trends for domestic substitution of imported products[1] Market Expansion and Strategy - The company has established sales and technical service networks both domestically and internationally to enhance market expansion[25] - The company is committed to a development strategy centered on systematization, internationalization, and digitalization[28] - The company plans to continue expanding its market presence and investing in new technologies and products, as indicated by the significant capital expenditures listed in the funding allocation[116] - The company aims to enhance its international market share while consolidating its domestic brand position[157] - The company plans to actively pursue mergers and acquisitions to accelerate growth in the life sciences and food equipment sectors[159] - The company is actively pursuing mergers and acquisitions to seek new growth points, despite potential risks associated with external acquisitions[176] Financial Position and Cash Flow - As of the end of 2022, cash and cash equivalents amounted to ¥4,710,070,214.21, representing 35.21% of total assets, an increase of 10.04% from the beginning of the year[78] - The company reported a significant increase in cash flow from financing activities, with a net cash flow of 2,428.31 million yuan, reflecting a 1102.78% increase compared to the previous year due to new share issuance[102] - The cash flow from operating activities was negative at approximately -¥166.69 million in Q1 2022, but turned positive in subsequent quarters[43] - The company’s cash flow from operating activities showed discrepancies due to increased receivables and higher inventory purchases, indicating a need for better cash management[103] - The cash inflow from operating activities was approximately ¥5.48 billion, a decrease of 8.1% from ¥5.97 billion in 2021[135] - The cash outflow from operating activities increased to approximately ¥5.24 billion in 2022, up 14% from ¥4.60 billion in 2021[135] Corporate Governance and Management - The company has established a governance structure that complies with the requirements set by the China Securities Regulatory Commission[200] - The company emphasizes integrity and compliance in its operations, aiming to enhance corporate governance and internal control systems[200] - The company has established a performance evaluation system for its board members and senior management to ensure transparency and compliance[182] - The company underwent a board restructuring on February 3, 2023, with several key personnel changes, including the election of new directors and supervisors[190] - The restructuring includes the appointment of a new financial director, Gao Zhijian, to strengthen financial management[190] - The company is committed to improving management efficiency and addressing operational challenges through enhanced management systems and platforms[160] Challenges and Risks - The company's international market share remains low due to challenges in funding scale, capacity construction, and process technology compared to leading foreign enterprises[56] - The pharmaceutical industry is undergoing rapid transformation, increasing competition and potential risks to the company's main business profitability[172] - The company acknowledges the risks posed by significant currency fluctuations due to its increasing export business[176]

Financial Performance - The total operating revenue for Q1 2023 was CNY 1,422,858,225.87, an increase of 14.87% compared to CNY 1,237,346,728.25 in Q1 2022[16] - The total operating costs for Q1 2023 were CNY 1,135,707,952.42, up 15.83% from CNY 980,425,006.32 in the same period last year[16] - The company's net profit for the current period is 243,338,626.35, an increase from 221,320,818.08 in the previous period, representing a growth of approximately 9.14%[18] - The total operating profit is reported at 274,411,481.41, compared to 252,461,174.32 in the previous period, indicating an increase of about 8.25%[18] - The total comprehensive income attributable to the parent company is 230,857,206.65, up from 211,450,946.94, reflecting a growth of approximately 9.73%[19] - Net profit attributable to shareholders was ¥231,048,479.97, up 9.26% from ¥211,462,634.61 year-over-year[35] - The net profit after deducting non-recurring gains and losses was ¥225,197,150.32, reflecting a 13.85% increase from ¥197,798,763.79 in the previous year[35] Cash Flow - The net cash flow from operating activities increased by 94.43% year-on-year, primarily due to a decrease in cash paid for purchasing goods[9] - The company reported a net cash outflow from operating activities of -9,291,858.17, an improvement from -166,688,330.83 in the previous period[31] - The cash inflow from operating activities totaled CNY 1,273,537,066.45, an increase of 2.4% compared to CNY 1,240,437,375.08 in the previous period[64] - The cash received from sales of goods and services was CNY 1,068,134,345.88, down 8.9% from CNY 1,172,484,201.60 in the prior period[64] - The cash paid for purchasing goods and services decreased by 26.2% to CNY 700,580,832.04 from CNY 949,822,649.50 in the previous period[64] - The cash received from tax refunds increased to CNY 7,445,654.79, up 39.4% from CNY 5,337,054.53 in the prior period[64] - The cash and cash equivalents at the end of the period stand at 3,862,207,001.03, compared to 2,397,657,876.66 at the end of the previous period, indicating an increase of approximately 61.19%[31] Assets and Liabilities - The company's total assets as of the end of Q1 2023 were CNY 13,264,581,712.38, a slight decrease from CNY 13,376,964,068.56 at the end of the previous year[16] - The total liabilities decreased to CNY 5,362,842,947.98 from CNY 5,732,944,396.41 in the previous year[16] - The company's cash and cash equivalents were CNY 3,865,472,995.94, down from CNY 4,710,070,214.21 in the previous year[14] - Inventory as of Q1 2023 was CNY 3,896,371,672.45, slightly down from CNY 3,899,309,956.37 in the previous year[15] - The company reported a significant increase in contract assets, which rose by 22.83% to CNY 394,737,047.69 from CNY 321,369,147.43 year-on-year[15] - The company's equity attributable to shareholders increased to CNY 7,685,291,362.16 from CNY 7,442,561,668.87 in the previous year[16] - Total assets at the end of the reporting period were ¥13,264,581,712.38, a decrease of 0.84% from ¥13,376,964,068.56 at the end of the previous year[36] - Shareholders' equity attributable to the parent company increased by 3.26% to ¥7,685,291,362.16 from ¥7,442,561,668.87 year-over-year[36] Investments and Financing - The company experienced a significant increase in financing cash flow, with a net increase of 398.36% compared to the previous year, primarily due to new investments from minority shareholders[23] - The company recorded an investment cash outflow of 953,986,240.85, a decrease from 1,041,982,673.15 in the previous period[31] - Financial expenses increased by 901.15% year-over-year, primarily due to an increase in interest income[39] - Investment income decreased by 96.44% compared to the previous year, mainly due to losses from associated companies[39] - The company reported a significant increase of 266.08% in trading financial assets, attributed to increased purchases of bank wealth management products[48] Shareholder Information - The total number of shareholders is 10, with the largest shareholder, Zheng Xiaodong, holding 34.31% of the shares[68] - The company plans to issue shares to specific investors, as approved by the Shenzhen Stock Exchange on July 13, 2022[72] Employee Compensation - The number of employees' performance bonuses paid in the current period led to a 39.28% decrease in payable employee compensation compared to the beginning of the period[67]